Beruflich Dokumente
Kultur Dokumente
Safe Harbor
Except for the historical information contained herein, statements in this presentation and the
subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”,
“would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”,
“contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue”
and similar expressions or variations of such expressions may constitute "forward-looking statements".
These forward-looking statements involve a number of risks, uncertainties and other factors that could
cause actual results to differ materially from those suggested by the forward-looking statements. These
risks and uncertainties include, but are not limited to our ability to successfully implement our strategy,
our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological
changes, investment and business income, cash flow projections, our exposure to market risks as well
as other risks. Ranbaxy does not undertake any obligation to update forward-looking statements to
Vision – 2012
Achieve significant business
in proprietary prescription products by 2012
with a strong presence in developed markets
Aspirations – 2012
• Aspire to be a $5 Billion Company
• Become a Top 5 Global Generics Player
• Significant Income from Proprietary Products
Values
• Manage our operations with high concern for safety and environment
• Ranbaxy & Daiichi Sankyo combined rank among the top 15 global
pharmaceutical companies
• Worldwide Presence
• Business
- International 80%
- Domestic 20%
• >12000 employees globally represented by 50 nationalities
Global Pharmaceutical Landscape
Global Pharma Market Slice
US $ Bn Global Pharmaceuticals Market:
• 2008: ~ US $ 726 Bn
35
65
72
Global Generics Market:
312
• 2008: US $ 78 Bn
242
Key Drivers of Generics:
• Patent Expiries
• New Markets
• Healthcare Costs
Product Portfolio
• Pressure on Vanilla Gx
• Move to Specialty/ Niche
Our Global Presence
• North America • Europe • Asia (incl. Middle East)
• Latin America • Africa • Japan
Business Model
Global Reach Product Portfolio
• Developed Markets • Generics
North America, EU, Japan, Australia • Branded Generics
• Emerging markets • Branded & OTC
India, Romania, CIS,
South Africa,
Brazil, Mexico Competitive Advantages
• Aggressive Marketing
• Low cost of Innovation
• Manufacturing Competitiveness
• Global Management
Research &
Development Manufacturing
* NDDS - Novel Drug Delivery System, API – Active Pharmaceutical Ingredients, FTF – First to File
Global Sales Split
CIS* Asia
North
America
RoW
API
Europe
FY 2005 FY 2008
Well established
Presence in 23 of 27 EU countries
No. 1 Generic player in Romania
Key markets - UK, France & Germany
Emerging Markets
12
Developed Markets Presence
• Largest generic market worldwide
• Significant patent expiries through 2011
USA
• Ranbaxy is ranked amongst top 10 generic companies
Source : IMS
Emerging Markets Presence
• Leadership position in domestic market
• Company growing faster than market
India
Source : IMS
India
R&D III
• R&D collaborations
Alliance / Alliance /
Collaboration in Collaboration in
NDDR NDDR
Out-licensing Out-licensing
In NDDR In NDDS
Our Global Manufacturing Strengths
• cGMP compliant world-class API & Dosage Forms manufacturing facilities across
the globe
• 10 manufacturing locations worldwide
• API facilities - increasing vertical integration
• Creating capacities for specialty products
• New facilities added in cost advantageous geographies
• Terapia (Romania)
• Based on the theme „Health For All‟ set up „Ranbaxy Rural Development Trust‟ in
1978; later re-christened as Ranbaxy Community Health Care Society (RCHS) in
1994
• Anti-Aids
– Provides innovative and affordable anti HIV medicines
– Over 500,000 patients worldwide on Ranbaxy ARV‟s
– First in the world Pediatrics ARV
• Malaria Research
– Molecule in Phase III Clinical Trials
– Intended for patients in developing countries
Corporate Governance
“An institutionalized framework of Corporate Governance and Code of
Practices to strengthen decision making and compliance with ethical
integrity and reliability”
Board Of Directors
Science Shareholder
Grievance/Transfer
Audit Compensation
Management
Thank You